Photo of Lorenzo Trippa,  PhD

Lorenzo Trippa, PhD

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute
Phone: (617) 733-9115


ltrippa@jimmy.harvard.edu

Lorenzo Trippa, PhD

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Assistant Professor, Biostatistics, Harvard T.H. Chan School Of Public Health
  • Assistant Professor, biostat, Dana-Farber Cancer Institute

DF/HCC PROGRAM AFFILIATION

Research Abstract

Lorenzo Trippa is Assistant professor at the Dana Farber Cancer Institute, Biostatistics and Computational Biology Department, and at the Harvard School of Public Health, Biostatistics Department. He is trained in statistics and his research interests include the design of efficient clinical trials. He is especially interested in clinical trials for studying personalized medicine. His research interests include also the analysis of data generated for complex Bayesian adaptive clinical trials. He is currently collaborating with physicians at DFCI on applying Bayesian adaptation to trials of glioblastoma, a form of brain cancer, and incorporating genomic information in designing Bayesian clinical trials. He is also collaborating with physicians at Massachusetts General Hospital to design innovative trials for melanoma targeted therapies.

Publications

Powered by Harvard Catalyst
  • Ramkissoon SH, Bi WL, Schumacher SE, Ramkissoon LA, Haidar S, Knoff D, Dubuc A, Brown L, Burns M, Cryan JB, Abedalthagafi M, Kang YJ, Schultz N, Reardon DA, Lee EQ, Rinne ML, Norden AD, Nayak L, Ruland S, Doherty LM, LaFrankie DC, Horvath M, Aizer AA, Russo A, Arvold ND, Claus EB, Al-Mefty O, Johnson MD, Golby AJ, Dunn IF, Chiocca EA, Trippa L, Santagata S, Folkerth RD, Kantoff P, Rollins BJ, Lindeman NI, Wen PY, Ligon AH, Beroukhim R, Alexander BM, Ligon KL. Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. 2015. PubMed
  • Trippa L, Wen PY, Parmigiani G, Berry DA, Alexander BM. Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials. 2015. PubMed
  • Marco E, Karp RL, Guo G, Robson P, Hart AH, Trippa L, Yuan GC. Bifurcation analysis of single-cell gene expression data reveals epigenetic landscape. Proc Natl Acad Sci U S A 2014; 111:E5643-50. PubMed
  • Bernau C, Riester M, Boulesteix AL, Parmigiani G, Huttenhower C, Waldron L, Trippa L. Cross-study validation for the assessment of prediction algorithms. Bioinformatics 2014; 30:i105-12. PubMed
  • Riester M, Wei W, Waldron L, Culhane AC, Trippa L, Oliva E, Kim SH, Michor F, Huttenhower C, Parmigiani G, Birrer MJ. Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. Journal of the National Cancer Institute 2014. PubMed
  • Alexander BM, Trippa L. Progression-free survival: too much risk, not enough reward? 2014; 16:615-6. PubMed
  • Wason JM, Trippa L. A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials. Stat Med 2014. PubMed
  • Parmigiani G, Boca S, Ding J, Trippa L. Statistical tools and R software for cancer driver probabilities. Methods Mol Biol 2013; 1101:113-34. PubMed
  • Lorenzo Trippa, Eudocia Q. Lee, Patrick Y. Wen, Tracy T. Batchelor, Timothy Cloughesy, Giovanni Parmigiani and Brian M. Alexander. Bayesian Adaptive Randomized Trial Design for Patients With Recurrent Glioblastoma J Clin Oncol 2012.